| EML4–ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib T Huang, BJ Engelmann, RM Morgan, KJ Absher, JM Kolesar, JL Villano Cancer Chemotherapy and Pharmacology 81, 965-968, 2018 | 7 | 2018 |
| Dose-dense temozolomide for recurrent high-grade gliomas: A single-center retrospective study CR Garcia, SA Slone, RM Morgan, L Gruber, SS Kumar, DD Lightner, ... Medical Oncology 35, 1-8, 2018 | 6 | 2018 |
| Hematological adverse events in the management of glioblastoma CR Garcia, ZW Myint, R Jayswal, C Wang, RM Morgan, AR Butts, ... Journal of neuro-oncology 156 (1), 153-161, 2022 | 4 | 2022 |
| Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials—impact of psychogenic non-epileptic seizures AM Morrow, RM Morgan, JL Villano Neuro-oncology 19 (7), 1010-1011, 2017 | 2 | 2017 |
| Oral Chemotherapy Program Metrics: Results of a National Survey OG Fahey, SY Barbour, MA Golf, DK Malard Johnson, RM Morgan, ... Journal of Hematology Oncology Pharmacy 13 (2), 85-94, 2023 | 1 | 2023 |
| Every three weekly irinotecan for refractory/relapsed small cell lung cancer. S Nutalapati, D Yan, R Morgan, A Chauhan Journal of Clinical Oncology 39 (15_suppl), e20584-e20584, 2021 | 1 | 2021 |
| Priming immunotherapy with radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC) and head and neck squamous cell cancer (HNSCC): Interim analysis of phase II … A Jacob, A Kreimer, J Wei, J Wu, L Corum, E Reusch, J Woodward, ... Journal of Clinical Oncology 39 (15_suppl), 2628-2628, 2021 | 1 | 2021 |
| Association of CDK4 amplification with duration of response to bevacizumab in glioblastoma. JL Villano, RM Morgan, S Zhang, J Kolesar, J Xiu, H Seifert, T Nicolaides, ... Journal of Clinical Oncology 41 (16_suppl), 2026-2026, 2023 | | 2023 |
| P63. 14 Three Weekly Irinotecan for Refractory/Relapsed Small Cell Lung Cancer S Nutalapati, D Yan, R Morgan, A Chauhan Journal of Thoracic Oncology 16 (10), S1188, 2021 | | 2021 |
| EPID-17. ANALYSIS OF THE USE OF BEVACIZUMAB FOR THE TREATMENT OF GLIOBLASTOMA IN THE UNITED STATES C Garcia, H Chitwood, C Harwood, B Shelton, R Morgan, L Vermuelen, ... Neuro-oncology, 2019 | | 2019 |
| CDK4 Amplification Associated with Longer Term Response to Bevacizumab in Glioblastoma JL Villano, RM Morgan, S Zhang, J Kolesar, J Xiu, H Seifert, T Nicolaides, ... | | |
